Effectiveness and safety of celecoxib combined with diacerein in the treatment of senile degenerative knee osteoarthritis: study protocol for a randomized controlled trial / 中国组织工程研究

BACKGROUND:The non-steroidal anti-inflammatory drug celecoxib,used for the treatment of senile degenerative knee osteoarthritis,has a rapid onset of action and few side effects.However,it cannot prevent the occurrence and development of knee osteoarthritis.Celecoxib withdrawal is likely to induce a rebound increase in inflammation that may aggravate symptoms.Diacerein is a drug used to improve articular cartilage metabolism.It can delay the progression of senile degenerative knee osteoarthritis,but has a slow onset of action.Whether combined treatment with celecoxib and diacerein provides complimentary actions to achieve a better therapeutic effect on senile degenerative knee osteoarthritis remains unclear.Whether combined treatment with celecoxib and diacerein provides complimentary actions to achieve a better therapeutic effect on senile degenerative knee osteoarthritis remains unclear.OBJECTIVE:To investigate the effectiveness and safety of celecoxib combined with diacerein in the treatment of senile degenerative knee osteoarthritis.METHODS:This is a prospective,single-center,randomized controlled trial.Three hundred patients with senile degenerative knee osteoarthritis who receive treatment at the Department of Orthopedics,Second Affiliated Hospital of Nanjing Medical University,China will be randomly assigned to celecoxib (200 mg,once a day,orally),diacerein (50 mg,twice a day,orally),and ccelecoxib+diacerein (celecoxib 200 mg,once a day,orally and diacerein 50 mg,twice a day,orally) groups,with 100 patients in each group.Patients in each group will be treated for 12 successive weeks,and a 36-week follow-up will be performed.The primary outcome measure of this study is the 20-meter walk pain visual analogue scale score before and 1,4,12,24,and 36 weeks after treatment.The secondary outcome measures of this study include osteoarthritis index and X-ray image findings of the knee before and 1,4,12,24,and 36 weeks after treatment,as well as the incidence of adverse events at 1,4,12,24,and 36 weeks after treatment.This study was approved by the Ethics Committee of the Second Affiliated Hospital of Nanjing Medical University,China (approval No.(2017)KY-091).The study protocol will be performed in strict accordance with the Declaration ofHelsinki formulated by the World Medical Association.Written informed consent of the study protocol and procedure will be obtained from each patient.Participant recruitment will begin in January 2018.Sample and data collection will begin in January 2018 and end in December 2018.Outcome measures will be analyzed in January 2020.The trial will end in February 2020.Results will be disseminated through presentations at scientific meetings and/or by publication in a peer-reviewed journal.This trial was registered with the Chinese Clinical Trial Registry (registration No.ChiCTR-IOR-17013867).DISCUSSION:Results from this study will help to determine whether celecoxib and diacerein complement each other to produce a long-acting,safe,reliable,and rapid-onset analgesic effect in patients with senile degenerative knee osteoarthritis.

Association of ERCC1 rs3212986 and ERCC2 rs13181 polymorphisms with the risk of glioma

Several previous studies have reported the role variant of ERCC1 rs3212986 and ERCC2 rs13181 polymorphisms in the risk of glioma, but the results of these studies are inconsistent. Therefore, we aimed to conduct a meta-analysis to investigate the role of ERCC1 rs3212986 and ERCC2 rs13181 on the risk of glioma. A comprehensive research was conducted through the databases of Pubmed, EMBASE and the China National Knowledge Infrastructure [CNKI] platforms until June 1, 2014, including 14 eligible case-control studies. Our meta-analysis found that ERCC1 rs3212986 AA genotype was significantly associated with increased risk of glioma compared with CC genotype, and the pooled OR [95%CI] was 1.29[1.07-1.55]. By subgroup analysis, ERCC1 rs3212986 AA genotype was found to be significantly correlated with increased glioma risk in Chinese population [OR=1.37, 95%CI=1.07, 1.55], Similarly, we found that ERCC2 rs13181 GT and TT genotypes were significantly associated with increased risk of glioma in Chinese population, with ORs [95%CI] of 1.47[1.17-1.85] and 1.50[1.02-2.22]. But ERCC1 rs3212986 and ERCC2 rs13181 polymorphisms had no significant association with glioma risk in Caucasian populations. By begg's funnel plot, we found that no publication bias was existed in this meta-analysis. Our meta-analysis suggested that ERCC1 rs3212986 and ERCC2 rs13181 polymorphism play an important risk factor for brain tumor development in Chinese population, but no association in Caucasian populations

MicroRNA-184 promotes proliferation ability of glioma cells by regulating FOXO3

OBJECTIVES@#To investigate the effect of microRNA (miR-184) on regulating the genesis, development and proliferation of glioma cells.@*METHODS@#Lipidosome was used to transfect miR-184 mimic and inhibitor to glioma cell line, and the cell proliferation ability changes were determined by MTT and plate cloning experiment after the transfection. WB test was used to measure the levels of cyclinD1, p27 and FOXO3. Meanwhile, QPCR was used to detect miR-184 expression in glioma cell line, glioma tissues and adjacent tissues. Luciferase experiment was used to test 3'UTR gene targeting regulation of miR-184 and FOXO3.@*RESULTS@#QPCR results showed a significant lower miR-184 expression level in glioma cell line and glioma tissues than that in juxtacancerous tissue. MTT and plate cloning experiments have shown that after over-expressing of miR-184, the cell proliferation capacity of glioma U87 and T98G was significantly increased, which was significantly inhibited after the inhibition of miR-184. WB results showed a lower expression level of p27 in U87 and T98G cells, and a higher expression level of cyclinD1 after over-expressing of miR-184 was observed. However, a lower expression level of cyclinD1 and a higher expression level of p27 after the inhibition of miR-184. The luciferase activity was inhibited after the over-expressing of miR-184.@*CONCLUSIONS@#MiR-184 can affect the proliferation abilities of glioma cells and regulate the cell cycle related protein. It plays an important role in the occurrence and development of gliomas.

The anti-HIV activity of three 2-alkylsulfanyl-6-benzyl-3, 4-dihydropyrimidin-4 (3H)-one derivatives acting as non-nucleoside reverse transcriptase inhibitor in vitro / 药学学报

It was recently shown that several new synthetic 2-alkylsulfanyl-6-benzyl-3, 4-dihydropyrimidin-4(3H)-one (S-DABO) derivatives demonstrated anti-HIV-1 activity. Three of the derivatives namely RZK-4, RZK-5 and RZK-6 were used in this study to explore their inhibitory effects on a variety of HIV strains. These compounds at a concentration of 200 microg mL(-1) almost completely inhibited the activity of recombinant HIV-1 reverse transcriptase. All of the three compounds reduced replication of HIV-1 laboratory-derived strains, low-passage clinical isolated strain, and the drug resistant strain. In particular RZK-6 showed potent activity against the HIV-1 drug resistant strain. In general, the antiviral activities are similar in magnitude to nevirapine (NVP), which is a non-nucleoside reverse transcriptase inhibitor approved by FDA. The therapeutic indexes of these compounds were remarkable, ranging from 3704 to 38462 indicating extremely low cytotoxicity. These results suggest that the three S-DABO derivatives in this study have good potential for further development in anti-HIV-1 therapy. It may be particularly useful to target at the non-nucleoside reverse transcriptase inhibitors resistant HIV-1 strain.

A clinical study of recombinant human granulocyte colony-stimulating factor on prevention of leukopenia caused by chemotherapy / 肿瘤研究与临床

Objective To observe the preventive value of recombinant human granulocyte colony stimulating factor(rhG-CSF)in cancer patients after chemotherapy.Methods In the open study,enrolled 52 patients with previously untreated cancer and with normal bone marrow function were randomly divided into 2 matched groups,A and B group.Each patient received one cycle of chemotherapy.In the study cycle,the pa- tients received a single subcutaneous injection of rhG-CSF 150 ?g before 24 hours of chemotherapy and in control cycle the patients only received chemotherapy.Efficacy and safety parameters were monitored.Results The incidence rates of leukopenia in the 26 valuable study cycles and 26 valuable control cycles were 19.23 % and 53.85 %,There were significant lower than those of group B(P

Diagnosis and differential diagnosis of Kallmann syndrome / 中华男科学杂志

<p><b>OBJECTIVE</b>To study diagnosis and differential diagnosis of Kallmann syndrome.</p><p><b>METHODS</b>The examinations including routine karyotyping, sex hormone, GnRH stimulation test and MRI were performed.</p><p><b>RESULTS</b>Cytogenetic analysis of his peripheral lymphocyte by G banding showed a normal male karyotype. GnRH stimulation test presented a good reaction. Plasma levels of luteinizing hormone (LH), follicle-stimulating hormone (FSH) and testosterone were very low. Absent olfactory bulb was found by magnetic resonance imaging (MRI).</p><p><b>CONCLUSION</b>Karyotype analysis, sexual hormone, GnRH stimulation test and MRI are very important the diagnosis of Kallmann syndrome.</p>